Reading Performance in Patients With Acrysof IQ Vivity Versus Acrysof IQ
NCT ID: NCT05194657
Last Updated: 2022-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
68 participants
INTERVENTIONAL
2022-01-03
2024-01-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vivity IOL: Emmetropia Compared to Monovision.
NCT05464732
Clinical Investigation of the AcrySof IQ Vivity Extended Vision Intraocular Lens (IOL)
NCT04098367
Visual Results of the Acrysof IQ Vivity Toric Extended Vision Intraocular Lens
NCT04652037
Myopic Monovision: EDOF vs. Monofocal IOL
NCT05194670
Performance of Two Intraocular Lenses With Extended Depth of Vision
NCT05194150
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Novel technology for providing an extended depth of focus (EDOF) has been developed to account for unmet needs of patients. A novel EDOF IOL, the Acrysof IQ Vivity, has two surface transition elements that work simultaneously by stretching and shifting the wavefront to create a continuous extended focal range instead of multiple focal points.
To assess the performance of such an IOL technology, most studies assess visual acuity at different distances from far, to intermediate up to near. Since most activites with digital devices implicate reading, it is not surprising that reading difficulty is the most common complaint among individuals experiencing visual disturbances with multifocal designs.
Reading ability is usually evaluated using various reading tests that assess reading speed and reading acuity defined as the print size that can stell be read with sufficient speed. However, one of the fundamental problems of these tests is that reading speed is also influenced by the average amount of time that a patient reads as well as the language of the text, whether it is the first or second language.
A novel method to analyse reading performance that appears to be more objective and less reliant on the cognitive abilities of the patient is the observation of the reading pattern using a high-speed eye-tracking system that analyses eye fixations during the reading test. In previous studies we have seen that several aspects of this reading patter, i.e. fixation duration and fixation frequency, appear to correlate with the reading performance overall and can be differentially used to discriminate between cognitive and visuo-motor processing.
Hence, the aim of this study is to assess the visual function and reading performance with an EDOF IOL (Acrysof IQ Vivity) compared to a standard monofocal IOL (Acrysof IQ).
136 eyes of 68 patients will be included into this study. According to the randomization, 34 patients will be implanted with the Acrysof IQ Vivity in both eyes and the other 34 patients will be implanted with the Acrysof IQ in both eyes. A follow-up examination will be performed at 3 months postoperative. During this visit a slitlamp examination, biometry and tomography of the eye, refraction and visual acuity assessment, an OCT examination, a retroillumination photogrypha, reading speed analysis and halometry will be performed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acrysof IQ Vivity
Patient will receive the enhanced depth of focus IOL during cataract surgery
enhanced depth of focus IOL
Acrysof IQ Vivity, enhanced depth of focus IOL
Acrysof IQ
Patiet will receive the monofocal IOL during cataract surgery
monofocal IOL
Acrysof IQ, monofocal IOL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
enhanced depth of focus IOL
Acrysof IQ Vivity, enhanced depth of focus IOL
monofocal IOL
Acrysof IQ, monofocal IOL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stereopsis
* age 21 and older
* regular corneal astigmatism of up to 3.0 D
* written informed consent prior to surgery
* normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
* availability, willingness and sufficient cognitive awareness to comply with examination procedures
* german as mother-tongue
* calculated IOL power needed is below 15.0 D or above 25.0 D (no high myopia or high hypermetropia will be recruited)
Exclusion Criteria
* amblyopia
* contact lenses
* irregular corneal astigmatism on corneal topography
* postoperative subjective refraction smaller/ higher than or 0.75 D
* pregnancy (pregnancy test will be taken preoperatively in women of reproductive age)
21 Years
105 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vienna Institute for Research in Ocular Surgery
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prim. Prof. Dr. Oliver Findl, MBA
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Oliver Findl, MD
Role: PRINCIPAL_INVESTIGATOR
Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital Vienna
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital Vienna
Vienna, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Vivity
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.